{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T19:07:56Z","timestamp":1774033676091,"version":"3.50.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Korea Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["RS-2022-CC125163"],"award-info":[{"award-number":["RS-2022-CC125163"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008746","name":"National Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008746","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.lungcan.2026.108916","type":"journal-article","created":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T22:45:16Z","timestamp":1768171516000},"page":"108916","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Durvalumab-containing treatment for recurrent or metastatic pulmonary sarcomatoid carcinoma: A pooled post hoc analysis of two KCSG phase II trials"],"prefix":"10.1016","volume":"213","author":[{"given":"Dong Hyun","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miso","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeonghwan","family":"Youk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gyeong-Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Se Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sook-Hee","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi Sun","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seong Hoon","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Wan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joo-Hang","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhumsuk","family":"Keam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2026.108916_b0005","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920950207","article-title":"Pulmonary sarcomatoid carcinoma: progress, treatment and expectations","volume":"12","author":"Li","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2026.108916_b0010","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1002\/1097-0142(19940615)73:12<2936::AID-CNCR2820731210>3.0.CO;2-U","article-title":"Pleomorphic (spindle\/giant cell) carcinoma of the lung. a clinicopathologic correlation of 78 cases","volume":"73","author":"Fishback","year":"1994","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2026.108916_b0015","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cllc.2016.03.001","article-title":"Characteristics and clinical outcomes of sarcomatoid carcinoma of the lung","volume":"17","author":"Ung","year":"2016","journal-title":"Clin. Lung Cancer"},{"issue":"3","key":"10.1016\/j.lungcan.2026.108916_b0020","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.surg.2012.05.007","article-title":"Outcomes of sarcomatoid carcinoma of the lung: a surveillance, epidemiology, and end results database analysis","volume":"152","author":"Yendamuri","year":"2012","journal-title":"Surgery"},{"issue":"12","key":"10.1016\/j.lungcan.2026.108916_b0025","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1097\/01.JTO.0000437008.00554.90","article-title":"Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma","volume":"8","author":"Vieira","year":"2013","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.108916_b0030","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.lungcan.2007.05.006","article-title":"Palliative chemotherapy for pulmonary pleomorphic carcinoma","volume":"58","author":"Bae","year":"2007","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.lungcan.2026.108916_b0035","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/COC.0000000000000101","article-title":"Characteristics and prognostic analysis of 69 patients with pulmonary sarcomatoid carcinoma","volume":"39","author":"Lin","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.108916_b0040","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919870360","article-title":"The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer","volume":"11","author":"Low","year":"2019","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2026.108916_b0045","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/JTO.0b013e318292be18","article-title":"Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1)","volume":"8","author":"Velcheti","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.108916_b0050","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.lungcan.2016.05.013","article-title":"Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages","volume":"98","author":"Vieira","year":"2016","journal-title":"Lung Cancer"},{"issue":"15","key":"10.1016\/j.lungcan.2026.108916_b0055","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1158\/1078-0432.CCR-16-3146","article-title":"PD-L1 studies across tumor types, its differential expression and predictive value in patients treated with immune checkpoint inhibitors","volume":"23","author":"Kluger","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2026.108916_b0060","doi-asserted-by":"crossref","first-page":"S1002","DOI":"10.1016\/j.annonc.2021.08.1894","article-title":"1292P two single-arm, multicenter phase-II trials of PD-1 inhibitors in patients with pulmonary sarcomatoid carcinoma (NCCH1603\/NCCH1703)","volume":"32","author":"Toyozawa","year":"2021","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2026.108916_b0065","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1111\/1759-7714.13684","article-title":"Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG\u2010LU16\u201007","volume":"11","author":"Kim","year":"2020","journal-title":"Thoracic Cancer"},{"key":"10.1016\/j.lungcan.2026.108916_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.cllc.2025.10.003","article-title":"A phase II study of durvalumab, doxorubicin, and ifosfamide in recurrent and\/or metastatic pulmonary sarcomatoid carcinoma (KCSG LU-19-24)","author":"Kim","year":"2025","journal-title":"Clin. Lung Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2026.108916_b0075","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/jama.2020.13042","article-title":"Pooling data from individual clinical trials in the COVID-19 era","volume":"324","author":"Petkova","year":"2020","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.lungcan.2026.108916_b0080","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s13142-016-0386-8","article-title":"Statistical methodologies to pool across multiple intervention studies","volume":"6","author":"Bangdiwala","year":"2016","journal-title":"Transl. Behav. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2026.108916_b0085","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41572-024-00551-9","article-title":"Non-small-cell lung cancer","volume":"10","author":"Hendriks","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"3","key":"10.1016\/j.lungcan.2026.108916_b0090","doi-asserted-by":"crossref","first-page":"635","DOI":"10.21037\/tlcr-24-127","article-title":"Biological characteristics and clinical treatment of pulmonary sarcomatoid carcinoma: a narrative review","volume":"13","author":"Wei","year":"2024","journal-title":"Transl. Lung Cancer Res."},{"issue":"10027","key":"10.1016\/j.lungcan.2026.108916_b0095","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.lungcan.2026.108916_b0100","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage IV or recurrent non\u2013small-cell lung cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.108916_b0105","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ejca.2020.03.029","article-title":"Outstanding clinical efficacy of PD-1\/PD-L1 inhibitors for pulmonary pleomorphic carcinoma","volume":"132","author":"Lee","year":"2020","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2026.108916_b0110","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jtho.2020.01.014","article-title":"Efficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma","volume":"15","author":"Domblides","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.108916_b0115","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.956982","article-title":"The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma","volume":"13","author":"Zeng","year":"2022","journal-title":"Front. Immunol."},{"issue":"17","key":"10.1016\/j.lungcan.2026.108916_b0120","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/1759-7714.14907","article-title":"Efficacy of immune checkpoint inhibitor therapy in patients with pulmonary sarcomatoid carcinoma in clinical practice","volume":"14","author":"Inomata","year":"2023","journal-title":"Thoracic Cancer"},{"issue":"8","key":"10.1016\/j.lungcan.2026.108916_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105343","article-title":"Efficacy of first-line treatments for advanced pulmonary sarcomatoid carcinomas: a real-world analysis","volume":"10","author":"Amrane","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.lungcan.2026.108916_b0130","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.lungcan.2018.06.009","article-title":"Efficacy of mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) in patients with advanced pulmonary pleomorphic carcinoma","volume":"122","author":"Lee","year":"2018","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.lungcan.2026.108916_b0135","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1016\/j.cllc.2017.12.008","article-title":"Sarcomatoid carcinoma of the lung: the Mayo Clinic experience in 127 patients","volume":"19","author":"Maneenil","year":"2018","journal-title":"Clin. Lung Cancer"},{"issue":"9","key":"10.1016\/j.lungcan.2026.108916_b0140","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.21037\/tlcr-24-263","article-title":"Efficacy of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma","volume":"13","author":"Birsen","year":"2024","journal-title":"Transl. Lung Cancer Res."},{"issue":"1","key":"10.1016\/j.lungcan.2026.108916_b0145","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","article-title":"The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors","volume":"7","author":"Davis","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.lungcan.2026.108916_b0150","series-title":"PD-L1 expression combined with immune phenotype is a potential predictor of outcome with PD-1 inhibitor monotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma","author":"Kim","year":"2025"},{"issue":"1","key":"10.1016\/j.lungcan.2026.108916_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtocrr.2023.100613","article-title":"Effectiveness and safety of immune checkpoint inhibitors alone or in combination with chemotherapy in pulmonary sarcomatoid carcinoma","volume":"5","author":"Hazama","year":"2024","journal-title":"JTO Clinical and Research Reports"},{"key":"10.1016\/j.lungcan.2026.108916_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114260","article-title":"Heterogeneity in advanced pulmonary sarcomatoid carcinoma and its efficacy to immune checkpoint inhibitors","volume":"209","author":"Xie","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.108916_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.108068","article-title":"Efficacy of immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma and predictive potential of mutated TP53","volume":"199","author":"Wu","year":"2025","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2026.108916_b0170","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40360-020-00404-7","article-title":"Favorable response to pembrolizumab after durvalumab failure in a stage III sarcomatoid carcinoma of the lung: a case report","volume":"21","author":"Nishino","year":"2020","journal-title":"BMC Pharmacol. Toxicol."},{"issue":"12","key":"10.1016\/j.lungcan.2026.108916_b0175","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.3390\/cancers12123625","article-title":"Integrating circulating biomarkers in the immune checkpoint inhibitor treatment in lung cancer","volume":"12","author":"Duchemann","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.lungcan.2026.108916_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110642","article-title":"Association of the CD4+\/CD8+ ratio with response to PD-1 inhibitor-based combination therapy and dermatological toxicities in patients with advanced gastric and esophageal cancer","volume":"123","author":"Xu","year":"2023","journal-title":"Int. Immunopharmacol."},{"issue":"7","key":"10.1016\/j.lungcan.2026.108916_b0185","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.3390\/ijms21072411","article-title":"Systemic blood immune cell populations as biomarkers for the outcome of immune checkpoint inhibitor therapies","volume":"21","author":"Hernandez","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.lungcan.2026.108916_b0190","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12943-023-01714-0","article-title":"Regulatory cells and the effect of cancer immunotherapy","volume":"22","author":"Iglesias-Escudero","year":"2023","journal-title":"Mol. Cancer"},{"issue":"30","key":"10.1016\/j.lungcan.2026.108916_b0195","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1111\/1759-7714.15089","article-title":"Artificial intelligence\u2010powered spatial analysis of tumor\u2010infiltrating lymphocytes as a biomarker in locally advanced unresectable thymic epithelial neoplasm: a single\u2010center, retrospective, longitudinal cohort study","volume":"14","author":"Kim","year":"2023","journal-title":"Thoracic Cancer"},{"issue":"12","key":"10.1016\/j.lungcan.2026.108916_b0200","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1002\/hed.27537","article-title":"Artificial intelligence\u2010powered spatial analysis of tumor\u2010infiltrating lymphocytes as a predictive biomarker for axitinib in adenoid cystic carcinoma","volume":"45","author":"Kim","year":"2023","journal-title":"Head Neck"},{"issue":"7","key":"10.1016\/j.lungcan.2026.108916_bib232","doi-asserted-by":"crossref","first-page":"4409","DOI":"10.21037\/jtd-2025-526","article-title":"Predictive role of tumor-infiltrating lymphocytes and immune phenotype for pembrolizumab in relapsed or refractory thymic carcinoma","volume":"17","author":"Kim","year":"2025","journal-title":"J. Thorac. Dis."},{"issue":"17","key":"10.1016\/j.lungcan.2026.108916_b0205","doi-asserted-by":"crossref","first-page":"9414","DOI":"10.3390\/ijms22179414","article-title":"Peripheral blood-based biomarkers for immune checkpoint inhibitors","volume":"22","author":"An","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.lungcan.2026.108916_b0210","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41416-023-02558-7","article-title":"Soluble lymphocyte activation gene-3 (sLAG3) and CD4\/CD8 ratio dynamics as predictive biomarkers in patients undergoing immune checkpoint blockade for solid malignancies","volume":"130","author":"Gorgulho","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.108916_b0215","article-title":"CD8+ tumor-infiltrating lymphocytes as a novel prognostic biomarker in lung sarcomatoid carcinoma, a rare subtype of lung cancer","volume":"3505\u20133511","author":"Chen","year":"2018","journal-title":"Cancer Manag. Res."},{"issue":"18","key":"10.1016\/j.lungcan.2026.108916_b0220","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.3390\/cells13181557","article-title":"Comparison of tumor microenvironments between primary tumors and lymph node metastases in head and neck squamous cell carcinoma and their predictive role in immune checkpoint inhibitor treatment","volume":"13","author":"Kim","year":"2024","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.lungcan.2026.108916_b0225","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s12672-024-01504-0","article-title":"Changes in the tumor microenvironment in recurrent head and neck squamous cell carcinoma and its implication on efficacy of immune checkpoint inhibitors","volume":"15","author":"Kim","year":"2024","journal-title":"Discov. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2026.108916_b0230","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.oooo.2024.07.014","article-title":"Predictive value of early dynamic changes of NLR and PLR for the efficacy of immune checkpoint inhibitor in head and neck squamous cell carcinoma","volume":"138","author":"Kim","year":"2024","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226000115?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226000115?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T18:05:12Z","timestamp":1774029912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226000115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":47,"alternative-id":["S0169500226000115"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.108916","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Durvalumab-containing treatment for recurrent or metastatic pulmonary sarcomatoid carcinoma: A pooled post hoc analysis of two KCSG phase II trials","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.108916","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108916"}}